The S&P 500 (^GSPC 0.94%) inched up 0.05% to 6,836.17 as cooler inflation data steadied sentiment. The Nasdaq Composite (^IXIC 1.02%) slipped 0.22% to 22,546.67, and the Dow Jones Industrial Average ...
Calpine agreed to supply 380 megawatts of power, grid connectivity and site infrastructure for a new CyrusOne data center to be built next to the Freestone Energy Center in Freestone County, with an ...
NEW YORK, Feb 6 (Reuters) - An artificial intelligence-driven shakeout in the heavyweight technology sector is set to keep stock investors on edge in the coming week while a barrage of data could ...
The shares of AI data center giant Applied Digital Corp (NASDAQ:APLD) are down 8.3% to trade at $28.91 at last check, a dismal outlook from semiconductor giant Qualcomm (QCOM) and increased AI ...
Financial data-provider stocks dropped after artificial-intelligence company Anthropic announced it added new functions for legal users of its Cowork assistant. While shares of European legal ...
For the first time in two years, Palantir Technologies Inc. shares are not rallying into a quarterly earnings report — a signal that investors are finding fewer reasons to snap up what has become one ...
Box, Inc. (NYSE:BOX) is one of the most promising cloud stocks according to analysts. On January 21, Citi analyst Steve Enders maintained his Buy rating on Box, Inc. (NYSE:BOX) stock, along with the ...
Our Privacy, Cyber & Data Strategy Team explores key changes to UK data protection rules introduced by the Data (Use and Access) Act 2025 and provides a checklist of ...
The UK government’s Department for Science, Innovation and Technology (DSIT) has completed what it calls the “discovery phase” of its bid to create a National Data Library (NDL). The NDL was trumpeted ...
Nvidia has invested $2 billion in AI infrastructure provider CoreWeave, the companies announced. Shares of CoreWeave popped on the news. Nvidia purchased CoreWeave Class A common stock at $87.20 per ...
Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results